STATEMENT UNDER 37 CFR 1.97(e) ACCOMPANYING Docket No. INFORMATION DISCLOSURE STA 9577-25 LAB In Re Application Of: (IDI ET AL OCT 2 5 2001 Serial No. Filing Date Examiner Group Art Unit 09/845497 05/01/2001 PRYOR, A 1616 Invention: EXT A RELEASE PHARMACEUTICALS TO THE ASSISTANT COMMISSIONER FOR PATENTS: This is a statement under the provisions of 37 CFR 1.97(e) in the above-identified application. Check applicable statement herebelow: Statement Under 37 CFR 1.97(e)(1) Each item of information contained in the accompanying Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the Information Disclosure Statement. Statement Under 37 CFR 1.97(e)(2) ☐ No item of information contained in the accompanying Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned person, after making reasonable inquiry, no item of information contained in the accompanying Information Disclosure Statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the Information Disclosure Statement. Dated: October 24, 2001 Lola A. Bartoszewicz, Ph.D. Certificate of Mailing by First Class Mail Registration No: 43394 certify that this document is being deposited on with the U.S. Postal Service as first class mail under 37 C.F.R. 1.8 and is addressed to the /2001 ENSUBAKI 50000053 09840497 Assistant Commissioner for Patents, Washington, D.C. :125 180.00 07 20231. Signature of Person Mailing Correspondence CC: Typed or Printed Name of Person Mailing Correspondence